RxDoctor Payments Data

Renee Bontrager

Family · Jackson, ALNPI 1164837563

Payments from drug & device makers

$1,565in general payments, 2019–2025

Across 62 payments — averaging $25.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$560
  • Lilly USA, LLC$247
  • Novo Nordisk$156
  • Merck$120
  • GSK$112
  • Takeda Pharmaceuticals U.S.A., Inc.$80
  • plus $289 from 9 others

What the payments were for

  • Food & beverage$1,52097%
  • Education$453%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca11$560
Lilly USA, LLC13$247
Novo Nordisk9$156
Merck7$120
GSK2$112
Takeda Pharmaceuticals U.S.A., Inc.4$80
Amgen4$67
Eisai Inc.2$44
Pfizer2$37
Bayer2$34
Atland Pharmaceuticals, LLC1$31
AbbVie2$26
Exact Sciences1$18
Genentech USA, Inc.1$18
Boehringer Ingelheim1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,565 in reported general payments places this provider in the 70th percentile of 3,415 family providers in Alabama.

See all family providers in Alabama

Medicare billing

Part B allowed, 2024
$26,099
Medicare patients
156
Services billed
3,558

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide76$105,794
FarxigaDapagliflozin Propanediol94$95,064
OzempicSemaglutide41$46,154
JardianceEmpagliflozin28$22,906
EliquisApixaban37$21,470
TrulicityDulaglutide22$20,490
LinzessLinaclotide23$18,452
EntrestoSacubitril/Valsartan11$16,742
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen380$10,376
SymbicortBudesonide/Formoterol Fumarate26$7,703
Colchicine35$3,443
Omeprazole165$2,274
Lantus SolostarInsulin Glargine,hum.Rec.Anlog21$2,112
Tizanidine Hcl148$1,640
Gabapentin101$1,525

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$247$126,28498 claims
AstraZenecaFarxiga, Symbicort$560$102,767120 claims
Novo NordiskOzempic$156$46,15441 claims
Boehringer IngelheimJardiance$15$22,90628 claims
PfizerEliquis$37$21,47037 claims
AbbVieLinzess$26$18,45223 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,415 family providers in Alabama.

Other family in Jackson

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →